



(12) Translation of
European patent specification

(11) NO/EP 2238170 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/28 (2006.01)
A61K 39/395 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.04.10
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.11.23
(86)	European Application Nr.	09705212.0
(86)	European Filing Date	2009.01.30
(87)	The European Application's Publication Date	2010.10.13
(30)	Priority	2008.01.31, EP, 08300061 2008.08.20, EP, 08162683
(84)	Designated Contracting States:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
(73)	Proprietor	INSERM - Institut National de la Santé et de la Recherche Médicale, 101, rue de Tolbiac, 75654 Paris Cedex, FR-Frankrike
(72)	Inventor	LEVY, Yves, Sce Immuno Clinique/Hôpital Henri Mondor 51 avenue Maréchal de Lattre de Tassigny, F-94010 Creteil, FR-Frankrike ELIAOU, Jean-François, Département d'Immunologie Hôpital Saint-Eloi CHRU Montpellier, 34295 Montpellier cedex 5, FR-Frankrike BENSUSSAN, Armand, Hôpital Saint-Louis Laboratory INSERM UMR-S 9761, avenue Claude Vellefaux, 75475 Paris cedex 10, FR-Frankrike BONNEFOY-BERARD, Nathalie, Inst. de Recherche en Cancérologie de Montpellier Equipe Immunité et Cancer INSERM U896-Université de Montpellier - CRLC Val d'Aurelle Campus Val d'Aurelle, 34298 Montpellier cedex 5, FR-Frankrike
(74)	Agent or Attorney	Bryn Aarflot AS, Postboks 449 Sentrum, 0104 OSLO, Norge

(54)	Title	ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF FOR INHIBITING T REGULATORY CELLS ACTIVITY
(56)	References Cited:	WO-A-2006/111986 US-A1- 2005 037 382 MÖLLER SINA ET AL: "Monitoring the expression of purinoceptors and nucleotide-metabolizing ecto-enzymes with antibodies directed against proteins in native conformation." PURINERGIC SIGNALLING SEP 2007, vol. 3, no. 4, September 2007 (2007-09), pages 359-366, XP019558228 ISSN: 1573-9538 DWYER ET AL.: "CD39 and control of cellular immune responses" PURINERGIC SIGNALLING, vol. 3, 6 February 2007 (2007-02-06), pages 171-180, XP002485580 DEAGLIO SILVIA ET AL: "Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression" JOURNAL OF EXPERIMENTAL MEDICINE, vol. 204, no. 6, June 2007 (2007-06), pages 1257-1265, XP002485581 ISSN: 0022-1007 SHEVACH ETHAN M ET AL: "The lifestyle of naturally occurring CD4(+)CD25(+)Foxp3(+) regulatory T cells" IMMUNOLOGICAL REVIEWS, vol. 212, August 2006 (2006-08), pages 60-73, XP002485582 ISSN: 0105-2896 SCHETINGER MARIA ROSA C ET AL: "NTPDase and 5'-nucleotidase activities in physiological and disease conditions: New perspectives for human health" BIOFACTORS, vol. 31, no. 2, 2007,

pages 77-98, XP009116149 ISSN: 0951-6433

Christian Dejaco ET AL: "Imbalance of regulatory T cells in human autoimmune diseases", Immunology, vol. 117, no. 3, 1 March 2006 (2006-03-01) , pages 289-300, XP055100105, ISSN: 0019-2805, DOI: 10.1111/j.1365-2567.2005.02317.x

SCHLOSSMANN ET AL., 1995, OXFORD UNIVERSITY PRESS, NEW YORK deel
GOUTTEFANGEAS ET AL.: 'Biochemical analysis and epitope mapping of mAb defining CD39', pages 383 - 385, XP009183240

DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US January 2009 MUNKONDA MERCEDES N ET AL: 'Characterization of a monoclonal antibody as the first specific inhibitor of human NTP diphosphohydrolase-3' Database accession no. PREV200900111448 & FEBS JOURNAL, vol. 276, no. 2, January 2009 (2009-01), pages 479-496, ISSN: 1742-464X(print), DOI: 10.1111/J.1742-4658.2008.06797.X

PAPAGNO ET AL.: "Immune Activation and CD8+ T-Cell Differentiation towards Senescence in HIV-1 Infection", PLOS BIOLOGY, vol. 2, February 2004 (2004-02), pages 173-185,

DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US June 2007 PEREZ-DIEZ AINHOA ET AL: 'CD4 cells can be more efficient at tumor rejection than CD8 cells' Database accession no. PREV200700458685 & BLOOD, vol. 109, no. 12, June 2007 (2007-06), pages 5346-5354, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2006-10-051318

DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US March 2010 QUEZADA SERGIO A ET AL: 'Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts' Database accession no. PREV201000196145 & JOURNAL OF EXPERIMENTAL MEDICINE, vol. 207, no. 3, March 2010 (2010-03), pages 637-650, ISSN: 0022-1007, DOI: 10.1084/JEM.20091918

DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US 20 July 1999 MUMBERG DOMINIK ET AL: 'CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma' Database accession no.

PREV199900384577 & MUMBERG DOMINIK ET AL: "CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 96, no. 15, 20 July 1999 (1999-07-20) , pages 8633-8638, ISSN: 0027-8424

DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US 01 December 2000 MARZO A L ET AL: 'Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity.' Database accession no.

NLM11086036 & MARZO A L ET AL: "Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 DEC 2000, vol. 165, no. 11, 1 December 2000 (2000-12-01), pages 6047-6055, ISSN: 0022-1767

DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US July 2005 KOZIEL MARGARET JAMES: 'Cellular immune responses against hepatitis C virus' Database accession no. PREV200510077570 & KOZIEL MARGARET JAMES: "Cellular immune responses against hepatitis C virus", CLINICAL INFECTIOUS DISEASES, vol. 41, no. Suppl. 1, July 2005 (2005-07) , pages S25-S31, ISSN: 1058-4838

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Anti-CD39-antistoff, omfattende:
 - en variabel lett kjede (VL) omfattende CDRene av VL-kjeden som kan oppnås fra hybridom deponert som CNCM-I-3889; og
 - en variabel tung kjede (VH) omfattende CDRene fra VH-kjeden som kan oppnås fra hybridom deponert som CNCM-I-3889,
 hvor nevnte antistoff hemmer T-regulerende celle (Treg) aktivitet.
2. Antistoff ifølge krav 1, hvor antistoffet omfatter:
 - en tung kjede variabel region som har aminosyresekvensen som angitt som SEKV ID NR: 1; og
 - en lett kjede variabel region som har aminosyresekvensen som angitt som SEKV ID NR: 5.
3. Antistoff ifølge hvilket som helst av kravene 1-2, hvor antistoffet er valgt fra gruppen bestående av et Fv, Fab, F(ab')₂, Fab', dsFv, scFv, sc(Fv)₂, en diabody og multispesifikke antistoffer dannet fra antistofffragmenter.
4. Antistoff ifølge krav 1, hvor antistoffet er et kimært eller humanisert antistoff.
5. Farmasøytisk preparat som omfatter et antistoff ifølge hvilket som helst av kravene 1 til 4 og en farmasøytisk akseptabel bærer.
6. Anti-CD39-antistoff ifølge hvilket som helst av kravene 1-4 for anvendelse for å behandle eller forebygge en sykdom valgt fra gruppen som består av cancere og infeksjonssykdommer.
7. Anti-CD39-antistoff for anvendelse ifølge krav 6, hvor nevnte sykdom er valgt fra gruppen bestående i lungecancer, brystcancer, eggstokkcancer, melanom, levercancer, magecancer, lymfecancer, tyroid cancer, gastrointestinal cancer, urogenital cancer og adenokarsinomer slik som koloncancer, nyre-cellecancer, prostatacancer, testikkeltumorer, ikke-småcellet karsinom i lungen, tynntarmscancer

og spiserørscancer.

8. Anti-CD39-antistoff for anvendelse ifølge krav 6, hvor nevnte sykdom er valgt fra gruppen bestående av infeksjon med virus, parasitter eller med bakterier.

5

9. Antistoff for anvendelse ifølge krav 8, hvor nevnte sykdom er valgt fra gruppen bestående av infeksjon med VIH, HBV, HCV, Plasmodium falciparum eller Mycobacterium tuberculosis.

10